Rajkot based pharmaceuticals startup, Anlon, a research-intensive organization which is into manufacturing of APIs and intermediates, process control instruments and pharmaceutical products has announced that it has presented at the BIO KOREA 2018 International Convention held on and from May 9-11, 2018, at COEX in Seoul in South Korea.
Anlon has already earned a global recognition for manufacturing products that adhere to the highest standards of quality. The company has three major divisions – Anlon Healthcare Private Limited which is into manufacturing of API and its intermediates, while Anlon Technology Research Organization is into manufacturing of process control and automation instruments and Anlon Lifescience Private Limited is engaged into multi dimensional modern pharmaceutical products.
Organized by the Korea Health Industry Development Institute (KHIDI) and North Chungcheong Province, Bio and Medical Korea 2018 meets its 13th anniversary enhancing the status of Korea’s bio-healthcare industry through various programs and promoting Korean pharmaceutical and medical device technology to the world.
“Advanced countries such as the U.S., Japan, China and Europe are introducing new strategies to nurture their healthcare industry,” South Korean Prime Minister Lee Nak-yeon said while inaugurating the event on May 9. “In line with such strategies, the government has already announced plans to foster the health industry as one of the key strategic industries.”
Lee emphasized that some of the government’s plans include leading the economic growth and creating jobs by raising pharmaceuticals, medical devices and cosmetics industry.
Some low-income people in medically advanced countries cannot receive treatment due to high medical expenses, South Korean Prime Minister said.
“The healthcare industry will surely bring hope to mankind while giving a sense of accomplishment to healthcare workers,” Lee said. “However, there are still challenges that the health industry should not ignore such as medical polarization.”
Commenting on the participation at the Bio and Medical Korea 2018, Mr. Punit Rasadia, Managing Director of Anlon said that though we are participating in Bio and Medical Korea for the first time, but we fully agree what Hon’ble Prime Minister of South Korea has said.
Mr. Rasadia said that Anlon is in the process of job creation by raising standards of pharmaceuticals and healthcare industry. In the last one year Anlon has created sizable number of job opportunities. With the expansion of Anlon, more jobs opportunities would be created.
Anlon Healthcare Private Limited has already created a niche in APIs and Intermediates production market. Anlon has completed compliance with all regulatory requirements of leading health authorities such as FDA, PMDA, KFDA, cGMP, WHO-GMP.
“We are also aware that in India too low-income people can’t receive treatment due to high medical expenses,” Mr. Rasadia said adding “Anlon is coming up with a solution to ensure medicines should reach to the poorest of the poor of this country.”
The exhibition, which involves 600 companies from 45 countries, offers more than 400 booths, business forums that deal with domestic and foreign companies, conferences where experts in various fields talk about the latest technology trends. The event will also include an “Invest Fair,” where domestic pharmaceuticals and medical device companies meet local and foreign investors.